Fumarate accumulation is well described as a driver of tumour aggressiveness in renal cancers that are fumarate hydratase-deficient, due to loss of heterozygosity of the enzyme or upregulation of the mammalian target of rapamycin (mTOR) [35–37]. Here, FH is linked to neoplasm.